178455-04-4

Basic information

• Product Name: (R)-BoroVal-(+)-Pinanediol-HCl
• Synonyms: (R)-BoroVal-(+)-Pinanediol-HCl;(3aS,4S,6S,7aR)-Hexahydro-3a,5,5-trimethyl-alpha-[(1R)-1-methylethyl]-4,6-methano-1,3,2-benzodioxaborole-2-methanamine hydrochloride
• CAS NO: 178455-04-4
• Molecular Formula: C₁₄H₂₆BNO₂*ClH
• Molecular Weight: 287.63368
• Mol File: 178455-04-4.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (R)-BoroVal-(+)-Pinanediol-HCl(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-BoroVal-(+)-Pinanediol-HCl(178455-04-4)
• EPA Substance Registry System: (R)-BoroVal-(+)-Pinanediol-HCl(178455-04-4)

Safety Data

• Hazardous Substances Data: 178455-04-4(Hazardous Substances Data)

Usage

General Description

(R)-BoroVal-(+)-Pinanediol-HCl is a chemical compound that consists of a boron-containing valine derivative bonded to a pinanediol molecule, and is in the form of a hydrochloride salt. It is commonly used as a catalyst in various organic chemical reactions, particularly in the enantioselective and stereospecific synthesis of chiral molecules. The compound's unique structure and properties make it a valuable tool in the production of pharmaceuticals, agrochemicals, and other fine chemicals. Additionally, (R)-BoroVal-(+)-Pinanediol-HCl has been studied for its potential applications in asymmetric organic synthesis and has shown promising results in catalyzing a diverse range of reactions with high efficiency and selectivity.

Upstream product

• 18680-27-8 pinanediol 
• 90084-26-7 (3aS,4S,6S,7aR)-2-isopropyl-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborole 

Relevant articles and documents

Structure-based development of (1-(3′-Mercaptopropanamido)methyl)boronic Acid Derived Broad-Spectrum, Dual-Action Inhibitors of Metallo- And Serine-β-lactamases

The emergence and spread of bacterial pathogens acquired metallo-β-lactamase (MBL) and serine-β-lactamase (SBL) medicated β-lactam resistance gives rise to an urgent need for the development of new dual-action MBL/SBL inhibitors. Application of a pharmacophore fusion strategy led to the identification of (2′S)-(1-(3′-mercapto-2′-methylpropanamido)methyl)boronic acid (MS01) as a new dual-action inhibitor, which manifests broad-spectrum inhibition to representative MBL/SBL enzymes, including the widespread VIM-2 and KPC-2. Guided by the VIM-2:MS01 and KPC-2:MS01 complex structures, further structural optimization yielded new, more potent dual-action inhibitors. Selectivity studies indicated that the inhibitors had no apparent inhibition to human angiotensin-converting enzyme-2 and showed selectivity across serine hydrolyases in E. coli and human HEK293T cells labeled by the activity-based probe TAMRA-FP. Moreover, the inhibitors displayed potentiation of meropenem efficacy against MBL- or SBL-positive clinical isolates without apparent cytotoxicity. This work will aid efforts to develop new types of clinically useful dual-action inhibitors targeting MBL/SBL enzymes.

BORONIC ACID DERIVATIVES AND USES THEREOF

This invention is directed to novel Boronic acid derivatives of Formula I, and pharmaceutically acceptable salts, solvate, solvate of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of Age-related Macular Degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, Wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor ceils. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry -AMD, Wet- AMD, and geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention. The compounds of the invention are inhibitors of HTRA1. Thus, the compounds of the invention are useful in the prevention and treatment of a wide range diseases mediated (in whole or in part) by HTRA1. The compounds of the invention are also useful for inhibiting HTRA1 protease activity in an eye or locus of an arthritis or related condition.